BR112015006571A2 - composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados - Google Patents

composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados

Info

Publication number
BR112015006571A2
BR112015006571A2 BR112015006571A BR112015006571A BR112015006571A2 BR 112015006571 A2 BR112015006571 A2 BR 112015006571A2 BR 112015006571 A BR112015006571 A BR 112015006571A BR 112015006571 A BR112015006571 A BR 112015006571A BR 112015006571 A2 BR112015006571 A2 BR 112015006571A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
prophylaxis
preparing
treatment
respiratory disorders
Prior art date
Application number
BR112015006571A
Other languages
English (en)
Inventor
Malhotra Geena
Purandare Shrinivas
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BR112015006571A2 publication Critical patent/BR112015006571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica, processo para preparar uma composiã‡ãƒo farmacãšutica, uso de uma composiã‡ãƒo farmacãšutica, e, mã‰todo para a profilaxia ou tratamento de asma, doenã‡a pulmonar obstrutiva crã”nica e distãšrbios respiratã“rios relacionados” a presente invenã§ã£o refere-se a uma composiã§ã£o farmacãªutica compreendendo tiotrã³pio, um propulsor de hidrofuoralcano (hfa) e opcionalmente um ou mais excipientes farmaceuticamente aceitã¡veis; a um processo para preparar uma composiã§ã£o farmacãªutica como esta e o uso desta na medicina, em particular para a profilaxia e tratamento de distãºrbios respiratã³rios.
BR112015006571A 2012-10-23 2013-10-23 composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados BR112015006571A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3092MU2012 2012-10-23
IN280MU2013 2013-01-31
PCT/GB2013/000454 WO2014064410A2 (en) 2012-10-23 2013-10-23 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR112015006571A2 true BR112015006571A2 (pt) 2017-07-04

Family

ID=54261200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006571A BR112015006571A2 (pt) 2012-10-23 2013-10-23 composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados

Country Status (10)

Country Link
US (1) US20150250713A1 (pt)
JP (1) JP2016503390A (pt)
KR (1) KR20150096371A (pt)
CN (1) CN104918604A (pt)
AU (1) AU2013336492A1 (pt)
BR (1) BR112015006571A2 (pt)
CA (1) CA2885767A1 (pt)
MX (1) MX2015003731A (pt)
WO (1) WO2014064410A2 (pt)
ZA (1) ZA201501930B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317040A1 (en) * 2015-08-31 2018-03-29 Mercator Medsystems, Inc. Local administration of drugs for the treatment of asthma
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
CN106880637B (zh) * 2015-12-15 2021-01-29 天津金耀集团有限公司 一种环索奈德福莫特罗噻托溴铵复方干粉吸入剂组合物
CN106880635B (zh) * 2015-12-15 2021-02-02 天津金耀集团有限公司 一种环索奈德福莫特罗干粉吸入剂组合物
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2018051128A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2554090A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical compound
US10792256B2 (en) 2016-09-19 2020-10-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
UA124240C2 (uk) * 2016-09-19 2021-08-11 Мехікем Флуор С.А. Де С.В. Фармацевтична композиція
JP6781831B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
CN114272238A (zh) 2016-09-19 2022-04-05 墨西哥氟石股份公司 药物组合物
US20210275439A1 (en) * 2018-06-07 2021-09-09 Kindeva Drug Delivery L.P. Fluticasone and vilanterol formulation and inhaler
US20210220367A1 (en) * 2020-01-20 2021-07-22 Cai Gu Huang Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochloride
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN113768906B (zh) * 2021-10-25 2023-05-09 上海方予健康医药科技有限公司 新型糖皮质激素吸入气雾剂及药物组件
EP4212106A1 (en) 2022-01-13 2023-07-19 Cuantum Medical Cosmetics, S.L. Handheld device for applying a cyanoacrylate adhesive composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311894B2 (en) * 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
WO2004054580A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
ES2259915B1 (es) 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
MX2011004730A (es) * 2008-11-04 2011-05-30 Cipla Ltd Composicion farmaceutica en aerosol.
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
WO2011076843A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
US20130274232A1 (en) * 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
WO2012093252A1 (en) * 2011-01-06 2012-07-12 Cipla Limited Pharmaceutical composition

Also Published As

Publication number Publication date
CA2885767A1 (en) 2014-05-01
WO2014064410A3 (en) 2014-08-07
KR20150096371A (ko) 2015-08-24
AU2013336492A1 (en) 2015-04-09
MX2015003731A (es) 2015-06-15
WO2014064410A2 (en) 2014-05-01
CN104918604A (zh) 2015-09-16
ZA201501930B (en) 2016-01-27
WO2014064410A8 (en) 2014-06-19
JP2016503390A (ja) 2016-02-04
US20150250713A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
MX2014013523A (es) Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos.
UY35963A (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CL2011000696A1 (es) Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
BR112013001119A2 (pt) composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
UY31687A1 (es) Nueva dosificacion y formulacion
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
PE20170073A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
ECSP055821A (es) Nueva formulacion pulverulenta que contiene tiotropio destinado a la inhalación
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
BR112016002222A2 (pt) partículas inaláveis compreendendo tiotrópio e indacaterol
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
CL2008000540A1 (es) Producto farmaceutico que comprende un compuesto derivado de heterociclo sustituido o herterociclo espiro condensado y un antagonista muscarinico; y su uso para el tratamiento de enfermedades de las vias aereas tales como epoc o asma.
BR112015004810A2 (pt) preparações de tiotrópio
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
PT115583A (pt) Processo contínuo para a preparação de medicamentos anticolinérgicos
BR112014003907A2 (pt) método para preparar inalador pulverizado de dose medida para tratar doença respiratória
CO2017004512A2 (es) Composición farmacéutica que contiene budesonida y formoterol
TR201620103A2 (tr) İnhalasyon i̇le uygulanan formülasyonlar
WO2014062143A3 (en) Combinations of glycopyrrolate and an anticholinergic agent

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]